ARCH un­veils its Re­al­ly Big Neu­ro­science Com­pa­ny with $500M, an Am­gen deal and eyes on de­pres­sion, Alzheimer's and a lot more

ARCH Ven­ture is dou­bling — and tripling and qua­dru­pling — down on the be­lief that the 2020s will be neu­ro­science’s decade.

The VC firm, known for pe­ri­od­i­cal­ly launch­ing mas­sive com­pa­nies from scratch, an­nounced on Thurs­day the cre­ation of Neumo­ra, a biotech ARCH’s part­ners be­lieve can fi­nal­ly crack a set of well-known neu­rode­gen­er­a­tive and psy­chi­atric dis­eases that have long elud­ed drug­mak­ers. The com­pa­ny, whose ex­is­tence was first re­port­ed by End­points News in Au­gust, emerges from stealth with $500 mil­lion in the bank — $400 mil­lion from ARCH and oth­er VCs and $100 mil­lion eq­ui­ty in­vest­ment as part of a col­lab­o­ra­tion with Am­gen.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER